{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:29:06Z","timestamp":1790076546048,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institutes of Allegy and Infectious Diseases","award":["5R44AI140708"],"award-info":[{"award-number":["5R44AI140708"]}]},{"name":"National Institutes of Allegy and Infectious Diseases","award":["5R44AI140708"],"award-info":[{"award-number":["5R44AI140708"]}]},{"name":"National Institutes of Allegy and Infectious Diseases","award":["5R44AI140708"],"award-info":[{"award-number":["5R44AI140708"]}]},{"name":"National Institutes of Allegy and Infectious Diseases","award":["5R44AI140708"],"award-info":[{"award-number":["5R44AI140708"]}]},{"name":"National Institutes of Allegy and Infectious Diseases","award":["5R44AI140708"],"award-info":[{"award-number":["5R44AI140708"]}]},{"name":"National Institutes of Allegy and Infectious Diseases","award":["5R44AI140708"],"award-info":[{"award-number":["5R44AI140708"]}]},{"name":"National Institutes of Allegy and Infectious Diseases","award":["5R44AI140708"],"award-info":[{"award-number":["5R44AI140708"]}]},{"name":"National Institutes of Allegy and Infectious Diseases","award":["5R44AI140708"],"award-info":[{"award-number":["5R44AI140708"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01497-7","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:13:50Z","timestamp":1783462430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A next-generation human lymphatic filariasis vaccine candidate, rBmHAXT, for clinical development"],"prefix":"10.1038","volume":"11","author":[{"given":"Nithila","family":"Saravanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad M.","family":"Puff-Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrick","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramaswamy","family":"Kalyanasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"1497_CR1","unstructured":"World Health Organization (WHO), https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lymphatic-filariasis (accessed 12 December 2025)."},{"key":"1497_CR2","doi-asserted-by":"publisher","first-page":"E44","DOI":"10.3390\/tropicalmed4010044","volume":"4","author":"K Pisarski","year":"2019","unstructured":"Pisarski, K. The global burden of disease of zoonotic parasitic diseases: top 5 contenders for priority consideration. Trop. Med. Infect. Dis. 4, E44 (2019).","journal-title":"Trop. Med. Infect. Dis."},{"key":"1497_CR3","unstructured":"Klion, A. Lymphatic filariasis: epidemiology, clinical manifestations, and diagnosis. UpToDate https:\/\/www.uptodate.com\/contents\/lymphatic-filariasis-epidemiology-clinical-manifestations-and-diagnosis#H8154366 (2019)."},{"key":"1497_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.pt.2019.08.003","volume":"35","author":"EL Davis","year":"2019","unstructured":"Davis, E. L., Reimer, L. J., Pellis, L. & Hollingsworth, T. D. Evaluating the evidence for lymphatic filariasis elimination. Trends Parasitol. 35, 860\u2013869 (2019).","journal-title":"Trends Parasitol."},{"key":"1497_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/tropicalmed3040105","volume":"3","author":"DK de Souza","year":"2018","unstructured":"de Souza, D. K. et al. Low microfilaremia levels in three districts in coastal ghana with at least 16 years of mass drug administration and persistent transmission of lymphatic filariasis. Trop. Med. Infect. Dis. 3, 105 (2018).","journal-title":"Trop. Med. Infect. Dis."},{"key":"1497_CR6","first-page":"29","volume":"15","author":"B Tripathi","year":"2022","unstructured":"Tripathi, B., Roy, N. & Dhingra, N. Introduction of triple-drug therapy for accelerating lymphatic filariasis elimination in India: lessons learned. Am. J. Trop. Med Hyg. 15, 29\u201338 (2022).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"1497_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijid.2018.11.350","volume":"79","author":"A Kumar","year":"2019","unstructured":"Kumar, A., Bajpei, A., Singh, T. & Masih, S. N. Mass drug administration (MDA) to eliminate lymphatic filariasis: even 100% coverage would fail to achieve elimination of infection in community in 6 years. Int. J. Inf. Dis. 79, 143 (2019).","journal-title":"Int. J. Inf. Dis."},{"key":"1497_CR8","first-page":"2","volume":"1","author":"S Swaminathan","year":"2008","unstructured":"Swaminathan, S., Subash, P. P., Rengachari, R., Kaliannagounder, K. & Pradeep, D. K. Mathematical models for lymphatic filariasis transmission and control: challenges and prospects. Parasit. Vectors 1, 2 (2008).","journal-title":"Parasit. Vectors"},{"key":"1497_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pt.2019.11.005","volume":"36","author":"R Kalyanasundaram","year":"2020","unstructured":"Kalyanasundaram, R., Khatri, V. & Chauhan, N. Advances in vaccine development for human lymphatic filariasis. Trends Parasitol. 36, 195\u2013205 (2020).","journal-title":"Trends Parasitol."},{"key":"1497_CR10","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.ijpara.2018.04.002","volume":"48","author":"V Khatri","year":"2018","unstructured":"Khatri, V. et al. Prospects of developing a prophylactic vaccine against human lymphatic filariasis - evaluation of protection in non-human primates. Int. J. Parasitol. 48, 773\u2013783 (2018).","journal-title":"Int. J. Parasitol."},{"key":"1497_CR11","doi-asserted-by":"publisher","first-page":"105487","DOI":"10.1016\/j.actatropica.2020.105487","volume":"208","author":"V Khatri","year":"2020","unstructured":"Khatri, V., Chauhan, N. & Kalyanasundaram, R. Fecundity of adult female worms were affected when Brugia malayi infected Mongolian gerbils were immunized with a multivalent vaccine (rBmHAXT) against human lymphatic filarial parasite. Acta Trop. 208, 105487 (2020).","journal-title":"Acta Trop."},{"key":"1497_CR12","doi-asserted-by":"publisher","first-page":"a013219","DOI":"10.1101\/cshperspect.a013219","volume":"4","author":"NJ Bulleid","year":"2012","unstructured":"Bulleid, N. J. Disulfide bond formation in the mammalian endoplasmic reticulum. Cold Spring Harb. Perspect. Biol. 4, a013219 (2012).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1497_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.4049\/jimmunol.1901173","volume":"205","author":"A Sachs","year":"2020","unstructured":"Sachs, A. et al. Impact of cysteine residues on MHC binding predictions and recognition by tumor-reactive T cells. J. Immunol. 205, 539\u2013549 (2020).","journal-title":"J. Immunol."},{"key":"1497_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3389\/fmicb.2014.00341","volume":"5","author":"GL Rosano","year":"2014","unstructured":"Rosano, G. L. & Ceccarelli, E. A. Recombinant protein expression in microbial systems. Front. Microbiol. 5, 341 (2014).","journal-title":"Front. Microbiol."},{"key":"1497_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1208\/s12249-018-1254-2","volume":"20","author":"N Dumpa","year":"2019","unstructured":"Dumpa, N. et al. Stability of vaccines. AAPS PharmSciTech 20, 42 (2019).","journal-title":"AAPS PharmSciTech"},{"key":"1497_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","volume":"42","author":"OS Kumru","year":"2014","unstructured":"Kumru, O. S. et al. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Biologicals 42, 237\u2013259 (2014).","journal-title":"Biologicals"},{"key":"1497_CR17","unstructured":"Centers for Disease Control and Prevention (CDC). Vaccine Storage and Handling Toolkit. https:\/\/www.cdc.gov\/vaccines\/hcp\/admin\/storage\/toolkit\/storage-handling-toolkit.pdf. (accessed 12 December 2025)."},{"key":"1497_CR18","unstructured":"World Health Organization. Guidelines on Stability Evaluation of Vaccines, Annex 3, TRS No 962 https:\/\/www.who.int\/publications\/m\/item\/guidelines-on-stability-evaluation-of-vaccines. (Accessed on 12 December 2025)."},{"key":"1497_CR19","unstructured":"European Medicines Agency. Guideline on clinical evaluation of vaccines. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-evaluation-vaccines-revision-1_en.pdf. (Accessed on 12 December 2025)."},{"key":"1497_CR20","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1080\/14760584.2021.1990760","volume":"20","author":"P Vivek","year":"2021","unstructured":"Vivek, P. et al. Lymphatic filariasis vaccine development: neglected for how long? Expert Rev. Vaccines 20, 1471\u20131482 (2021).","journal-title":"Expert Rev. Vaccines"},{"key":"1497_CR21","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00436-017-5593-9","volume":"116","author":"N Chauhan","year":"2017","unstructured":"Chauhan, N. et al. Improving the efficacy of a prophylactic vaccine formulation against lymphatic filariasis. Parasitol. Res. 116, 2821\u20132830 (2017).","journal-title":"Parasitol. Res."},{"key":"1497_CR22","doi-asserted-by":"crossref","unstructured":"Kalyanasundaram, R. Lymphatic filariasis: current status of elimination using chemotherapy and the need for a vaccine. In Communicable Diseases of the Developing World. Topics in Medicinal Chemistry Ch 03 (ed. Saxena, A. K.) Vol. 29, 1\u201336 (Springer, 2016).","DOI":"10.1007\/7355_2015_5002"},{"key":"1497_CR23","doi-asserted-by":"crossref","unstructured":"Kalyanasundaram, R. Next step lymphatic filariasis eradication: current status in the development of a vaccine against lymphatic filariasis, lymphatic filariasis (ed. Tyagi, B. K.) 59\u201380 (Springer Nature, 2018).","DOI":"10.1007\/978-981-13-1391-2_3"},{"key":"1497_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1046\/j.1365-3024.2001.00396.x","volume":"23","author":"RA Lawrence","year":"2001","unstructured":"Lawrence, R. A. & Devaney, E. Lymphatic filariasis: parallels between the immunology of infection in humans and mice. Parasite Immunol. 23, 353\u2013361, https:\/\/doi.org\/10.1046\/j.1365-3024.2001.00396.x (2001).","journal-title":"Parasite Immunol."},{"key":"1497_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/sji.12533","volume":"85","author":"A Kwarteng","year":"2017","unstructured":"Kwarteng, A. & Ahuno, S. T. Immunity in filarial infections: lessons from animal models and human studies. Scand. J. Immunol. 85, 251\u2013257 (2017).","journal-title":"Scand. J. Immunol."},{"key":"1497_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/pim.12081","volume":"36","author":"S Babu","year":"2014","unstructured":"Babu, S. & Nutman, T. B. Immunology of lymphatic filariasis. Parasite Immunol. 36, 338\u2013346 (2014).","journal-title":"Parasite Immunol."},{"key":"1497_CR27","doi-asserted-by":"publisher","first-page":"A54","DOI":"10.1016\/S0167-5699(05)80016-7","volume":"12","author":"CL King","year":"1991","unstructured":"King, C. L. & Nutman, T. B. Regulation of the immune response in lymphatic filariasis and onchocerciasis. Immunol. Today 12, A54\u2013A58 (1991).","journal-title":"Immunol. Today"},{"key":"1497_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1046\/j.1365-3024.2001.00399.x","volume":"23","author":"TB Nutman","year":"2001","unstructured":"Nutman, T. B. & Kumaraswami, V. Regulation of the immune response in lymphatic filariasis: perspectives on acute and chronic infection with Wuchereria bancrofti in South India. Parasite Immunol. 23, 389\u201399 (2001).","journal-title":"Parasite Immunol."},{"key":"1497_CR29","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1017\/S0031182000075259","volume":"104","author":"EA Ottesen","year":"1992","unstructured":"Ottesen, E. A. The Wellcome Trust Lecture. Infection and disease in lymphatic filariasis: an immunological perspective. Parasitology 104, S71\u201379 (1992).","journal-title":"Parasitology"},{"key":"1497_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1102121","volume":"13","author":"M Ritter","year":"2022","unstructured":"Ritter, M. & H\u00fcbner, M. P. Editorial: host immune response and protective immune responses during filarial infections. Front. Immunol. 13, 1102121 (2022).","journal-title":"Front. Immunol."},{"key":"1497_CR31","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.3389\/fimmu.2018.01520","volume":"9","author":"N Chauhan","year":"2018","unstructured":"Chauhan, N., Khatri, V., Banerjee, P. & Ramaswamy, K. Evaluating the vaccine potential of a tetravalent fusion protein (rBmHAXT) vaccine antigen against lymphatic filariasis in a mouse model. Front. Immunol. 9, 1520 (2018).","journal-title":"Front. Immunol."},{"key":"1497_CR32","doi-asserted-by":"publisher","first-page":"e112982","DOI":"10.1371\/journal.pone.0112982","volume":"9","author":"G Dakshinamoorthy","year":"2014","unstructured":"Dakshinamoorthy, G., von Gegerfelt, A., Andersen, H., Lewis, M. & Kalyanasundaram, R. Evaluation of a multivalent vaccine against lymphatic filariasis in rhesus macaque model. PLoS ONE 9, e112982 (2014).","journal-title":"PLoS ONE"},{"key":"1497_CR33","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.vaccine.2012.09.055","volume":"31","author":"G Dakshinamoorthy","year":"2013","unstructured":"Dakshinamoorthy, G., Samykutty, A. K., Munirathinam, G., Reddy, M. V. & Kalyanasundaram, R. Multivalent fusion protein vaccine for lymphatic filariasis. Vaccine 31, 1616\u20131622 (2013).","journal-title":"Vaccine"},{"key":"1497_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.63","volume":"5","author":"D Carter","year":"2016","unstructured":"Carter, D. et al. A structure- function approach to optimizing TLR4 ligands for human vaccines. Clin. Transl. Immunol. 5, e108 (2016).","journal-title":"Clin. Transl. Immunol."},{"key":"1497_CR35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao, T. et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct. Target Ther. 8, 283 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1497_CR36","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., S. Arunachalam, P. & O\u2019Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1497_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fitd.2022.998353","volume":"3","author":"V Melendez","year":"2022","unstructured":"Melendez, V. et al. Pre-clinical development of a vaccine for human lymphatic filariasis. Front. Trop. Dis. 3, 998353 (2022).","journal-title":"Front. Trop. Dis."},{"key":"1497_CR38","first-page":"2654","volume":"41","author":"K Takayama","year":"1981","unstructured":"Takayama, K., Ribi, E. & Cantrell, J. L. Isolation of a nontoxic lipid a fraction containing tumor regression activity. Cancer Res. 41, 2654\u20132657 (1981).","journal-title":"Cancer Res."},{"key":"1497_CR39","doi-asserted-by":"publisher","first-page":"7676","DOI":"10.1016\/j.vaccine.2022.11.002","volume":"40","author":"SA Lukehart","year":"2022","unstructured":"Lukehart, S. A. et al. Immunization with a tri-antigen syphilis vaccine significantly attenuates chancre development, reduces bacterial load, and inhibits dissemination of Treponema pallidum. Vaccine 40, 7676\u20137692 (2022).","journal-title":"Vaccine"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01497-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01497-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01497-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T18:00:19Z","timestamp":1787421619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01497-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1497"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01497-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6572437\/v1","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"171"}}